Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to non-small cell lung cancer (NSCLC) patients.
The post Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC appeared first on Clinical Trials Arena .